Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials

International Journal of Cardiology

Volumn 216, Issue , 2016, Pages 168-172

  Proietti, Marco ^a   Lane, Deirdre A ^a   Lip, Gregory Y H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Anticoagulation control; Atrial fibrillation; Warfarin

Indexed keywords

WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SAME TT2R2 SCORE; SCORING SYSTEM; SURVIVAL ANALYSIS; THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K;

EID: 84975317408     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.04.131     Document Type: Article

References (27)

1. A.J. Camm, G.Y.H. Lip, R. De Caterina, I. Savelieva, D. Atar, S.H. Hohnloser, and et al. Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur. Heart J. 33 2012 2012 2719 2747
2. S. Husted, R. de Caterina, F. Andreotti, H. Arnesen, F. Bachmann, K. Huber, and et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel Thromb. Haemost. 111 2014 781 782
3. G.Y.H. Lip, C. Laroche, G.A. Dan, M. Santini, Z. Kalarus, L.H. Rasmussen, and et al. "Real-World" antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey Am. J. Med. 127 2014 519-29.e1
4. M.V. Huisman, K.J. Rothman, M. Paquette, C. Teutsch, H.C. Diener, S.J. Dubner, and et al. Antithrombotic treatment patterns in 10,871 patients with newly diagnosed non-valvular atrial fibrillation: the GLORIA-AF registry program, phase II Am. J. Med. 2015 10.1016/j.amjmed.2015.07.013
5. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and E. Briët A method to determine the optimal intensity of oral anticoagulant therapy Thromb. Haemost. 69 1993 236 239 (http://www.ncbi.nlm.nih.gov/pubmed/8470047 (accessed April 8, 2015))
6. M.A. Esteve-Pastor, V. Roldán, M. Valdés, G.Y.H. Lip, and F. Marín The SAMe-TT2R2 score and decision making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation Expert. Rev. Cardiovasc. Ther. 2015 10.1586/14779072.2016.1116941
7. K. Senoo, Y.C. Lau, and G.Y. Lip Updated NICE guideline: management of atrial fibrillation (2014) Expert. Rev. Cardiovasc. Ther. 12 2014 1037 1040
8. R. De Caterina, S. Husted, L. Wallentin, F. Andreotti, H. Arnesen, F. Bachmann, and et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III) Thromb. Haemost. 110 2013 1087 1107
9. A.M. Shields, and G.Y.H. Lip Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation J. Intern. Med. 278 2015 1 18
10. G.Y.H. Lip, and D.A. Lane Stroke prevention in atrial fibrillation JAMA 313 2015 1950 1962
11. L. Azoulay, S. Dell'aniello, T.A. Simon, C. Renoux, and S. Suissa Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes Eur. Heart J. 35 2014 1881 1887
12. 2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation Chest 146 2014 719 726
13. 2 score Chest 144 2013 1555 1563
14. M. Proietti, and G.Y.H. Lip Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score Eur. Hear. J. Cardiovasc. Pharmacother. 1 2015 150 152
15. D. Poli, E. Antonucci, S. Testa, and G.Y.H. Lip A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin Intern. Emerg. Med. 9 2014 443 447
16. P. Gallego, V. Roldán, F. Marin, J. Gálvez, M. Valdés, V. Vicente, and et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation Am. J. Med. 127 2014 1083 1088
17. V. Roldán, S. Cancio, J. Gálvez, M. Valdés, V. Vicente, F. Marín, and et al. The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective "Real-world" inception cohort study Am. J. Med. 128 2015 1237 1243
18. R.R.-Y. Abumuaileq, E. Abu-Assi, S. Raposeiras-Roubin, A. Lopez-Lopez, A. Redondo-Dieguez, D. Alvarez-Iglesias, and et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists Europace 17 2015 711 717
19. M. Ruiz-Ortiz, V. Bertomeu, Á. Cequier, F. Marín, and M. Anguita Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists Thromb. Haemost. 114 2015 10.1160/TH15-02-0169
20. L. Fauchier, D. Poli, and B. Olshansky The SAMe-TT2R2 score and quality of anticoagulation in AF: can we predict which patient benefits from anticoagulation? Thromb. Haemost. 114 2015 657 659
21. G. Palareti, E. Antonucci, G.Y.H. Lip, S. Testa, G. Guazzaloca, A. Falanga, and et al. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE Thromb. Haemost. 115 2016 10.1160/TH15-10-0830
22. J.L. Halperin Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) Am. Heart J. 146 2003 431 438
23. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698 (http://www.ncbi.nlm.nih.gov/pubmed/14643116 (accessed April 20, 2015))
24. G.W. Albers, H.-C. Diener, L. Frison, M. Grind, M. Nevinson, S. Partridge, and et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690 698
25. G.Y.H. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J.G.M. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
26. J.M. Lobos-Bejarano, V. Barrios-Alonso, J. Polo-García, C. Escobar-Cervantes, D. Vargas-Ortega, N. Marín-Montañés, and et al. Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain Curr. Med. Res. Opin. 2016 1 29
27. P.H. Chan, J.J. Hai, E.W. Chan, W.H. Li, H.F. Tse, I.C.K. Wong, and et al. Use of the SAMe-TT2R2 score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence PLoS One 11 2016 e0150674